Clinical trials offer patients the very latest in cancer care, while giving physicians and researchers the opportunity to study the effectiveness of the treatment. The Capital Health Center for Oncology participates in many National Cancer Institute, University and Pharmaceutical Phase III clinical trials. Our oncologists and research nurses carefully review the study criteria, potential benefits, risks, and other considerations with eligible patients before enrolling in a clinical study. The staff in our Clinical Research Department will carefully monitor you throughout the clinical trial and answer any questions you may have about the trial.
Please contact Linda Andrzejewski at 609-537-7042 or e-mail her at email@example.com for more information.
Clinical Trials currently being offered:
RTOG 1005 A Phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent boost versus standard whole breast irradiation plus sequential boost for early-stage breast cancer
SWOG/CALGB C80702 A Phase III trial of six versus 12 treatments of adjuvant FOLFOX plus Celecoxib or placebo for patients with resected stage III colon cancer
NSABP P-5 A statin polyp prevention trial in patients with resected colon cancer
Establishing an anticipatory model for anxiety and depression through a screening tool for first-time radiation oncology patients
SWOG 0931 (EVEREST) A Phase III study, Everolimus for renal cancer ensuing surgical therapy
CALGB 90601 A randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin and placebo in patients with advanced transitional cell carcinoma
The Capital Health CyberKnife® Center continues to enhance clinical care through research by providing the most current treatment options in radiotherapy and CyberKnife radiosurgery. We currently participate in several clinical trials initiated at leading academic medical centers throughout the country and are in the process of initiating novel investigations involving the use of the CyberKnife with the hope of meeting the needs of our community and improving our patients’ cancer outcomes.
Current Active Clinical Trials:
- CK Brain Mets-01 - A Phase II consensus multi-institutional trial of CyberKnife Radiosurgery to the operative cavity in patients with resected brain metastases. (Clinical Trial)
This clinical trial is open to all patients who have brain metastases, who are older than 18 years of age and have not previously received whole brain radiation. The standard treatment for patients who have tumor metastasis to the brain may include surgery and various forms of radiation therapy. Unfortunately, in the past, these treatments were not curative and could be toxic. This study is being done to evaluate a novel CyberKnife treatment combination for one to three metastatic cancerous tumors in the brain. The protocol involves surgery followed by focused beams of CyberKnife radiation. If you think you may qualify for this trial or have any further questions, please ask our radiation oncologist for more explanation about this study.
- RTOG 0938 - A randomized Phase II trial of hypofractionated radiotherapy for favorable risk prostate cancer
- RTOG 0631 - Phase II/III study of image-guided radiosurgery/SBRT for localized spine metastasis